Actively Recruiting

Phase Not Applicable
Age: 21Years - 85Years
All Genders
NCT05780710

OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake

Led by Aktiia SA · Updated on 2026-02-05

35

Participants Needed

3

Research Sites

183 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Study design: Prospective, multicentric, randomized, comparative study Study duration: between 4 and 19 weeks depending on the study group. Population: minimum 35 hypertensives (stage 1 or stage 2) participants divided into 3 groups depending on hypertension criteria. GROUP 1 = untreated hypertensives, stage 1 or stage 2; GROUP 2 = hypertensives, stage 1, who are taking antihypertensive monotherapy; GROUP 3 = hypertensives, stage 1 or stage 2, who are taking antihypertensive treatment that doesn't allow them to have controlled blood pressure. Device Under Test (DUT): Aktiia device Reference: HBPM (Aktiia cuff) Periods of treatment: For GROUPS 1 and 2, 2 weeks of treatment for each antihypertensive medication followed by a washout period of 2 weeks (3 antihypertensive medications in total with a fixed dose; medication intake order is randomly assigned). For GROUP 3, an individualized new antihypertensive medication will be prescribed during the consultation with the investigator that will be administered for 3 weeks.

CONDITIONS

Official Title

OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake

Who Can Participate

Age: 21Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 21 to 85 years
  • Able to read and speak French
  • Own a smartphone using iOS or Android
  • Diagnosed with Stage 1 (SBP 140-159 mmHg or DBP 90-99 mmHg) or Stage 2 (SBP 160-179 mmHg or DBP 100-109 mmHg) hypertension, or SBP 60 mmHg if older than 65
  • No antihypertensive drugs taken in the 3 months prior to study start and during the study except study medications
  • Willing to attend all 4 on-site visits and follow study procedures
  • Signed informed consent form
Not Eligible

You will not qualify if you...

  • Contraindications to study drugs
  • Hypertension Stage 3 (SBP/DBP >180/110 mmHg)
  • Orthostatic hypotension (significant BP drop when standing)
  • Unable to perform required home blood pressure monitoring at set times
  • Medical interventions or treatments affecting blood pressure during study
  • For Groups 1 and 2: Target organ damage (left ventricular hypertrophy or high albumin/creatinine ratio)
  • Resting heart rate above 120 bpm
  • Atrial fibrillation
  • Cardiomyopathy with ejection fraction below 40%
  • Severe valvular heart disease
  • Implanted pacemaker or defibrillator
  • Diabetes
  • Renal dysfunction (eGFR < 45 mL/min/1.73 m2)
  • Hyperthyroidism or hypothyroidism
  • Pheochromocytoma
  • Raynaud's disease
  • Presence of arteriovenous fistula
  • Known pregnancy
  • Trembling or shivering
  • Lymphoedema
  • Abnormal potassium levels (<3.5 or >4.8 mmol/L)
  • Presence of intravascular device
  • Exfoliative skin diseases
  • Arm paralysis or amputation
  • Upper arm circumference below 22 cm or above 42 cm
  • Wrist circumference above 23 cm
  • Non-standard circadian rhythm including shift or night workers
  • Previous mastectomy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

HUG

Geneva, Canton of Geneva, Switzerland, 1205

Terminated

2

CHVR

Sion, Valais, Switzerland, 1951

Withdrawn

3

CHUV

Lausanne, Switzerland, 1011

Actively Recruiting

Loading map...

Research Team

C

Cléo Moulin, Master

CONTACT

P

Pascale Vermare, Master

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here